Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/a-novel-approach-to-cancer-therapy-using-px-478-as-a-hif-1-inhibitor-vRKruSVG10
References (12)
-
Ji-Won Lee, Seong-Hui Bae, Joo-Won Jeong, Se-Hee Kim, Kyu-Won Kim (2004)
Hypoxia-inducible factor (HIF-1)α: its protein stability and biological functionsExperimental & Molecular Medicine, 36
-
G. Hart, J. Lowe, N. Sathyamoorthy (2004)
Glycobiology and Cancer: Meeting Summary and Future DirectionsCancer Biology & Therapy, 3
-
S. Welsh, Ryan Williams, L. Kirkpatrick, G. Paine-Murrieta, G. Powis (2004)
Antitumor activity and pharmacodynamic properties of PX-478, an inhibitor of hypoxia-inducible factor-1αMolecular Cancer Therapeutics
-
D. Aebersold, P. Burri, K. Beer, J. Laissue, V. Djonov, R. Greiner, G. Semenza (2001)
Expression of hypoxia-inducible factor-1alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer.Cancer research, 61 7
-
A. Kung, Stream Wang, J. Klco, W. Kaelin, D. Livingston (2000)
Suppression of tumor growth through disruption of hypoxia-inducible transcriptionNature Medicine, 6
-
D. Schwartz, J. Bankson, Robert Lemos, S. Lai, A. Thittai, Yi He, G. Hostetter, M. Demeure, D. Hoff, G. Powis (2010)
Radiosensitization and Stromal Imaging Response Correlates for the HIF-1 Inhibitor PX-478 Given with or without Chemotherapy in Pancreatic CancerMolecular Cancer Therapeutics, 9
-
R. Tibes, G. Falchook, D. Hoff, G. Weiss, T. Iyengar, R. Kurzrock, L. Pestano, A. Lowe, R. Herbst (2010)
Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1{alpha}.Journal of Clinical Oncology, 28
-
B. Onnis, A. Rapisarda, G. Melillo (2009)
Development of HIF-1 inhibitors for cancer therapyJournal of Cellular and Molecular Medicine, 13
-
D. Schwartz, G. Powis, Arun Thitaikumar, Yi He, J. Bankson, Ryan Williams, Robert Lemos, Junghwan Oh, A. Volgin, S. Soghomonyan, R. Nishii, M. Alauddin, Uday Mukhopadhay, Zhenghong Peng, W. Bornmann, J. Gelovani (2009)
The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effectsMolecular Cancer Therapeutics, 8
-
V. Belozerov, Erwin Meir (2005)
Hypoxia inducible factor-1: a novel target for cancer therapyAnti-Cancer Drugs, 16
-
G. Macpherson, William II (2004)
Small Molecule-Mediated Anti-Cancer Therapy via Hypoxia Inducible Factor-1 BlockadeCancer Biology & Therapy, 3
-
M. Koh, T. Spivak-Kroizman, S. Venturini, S. Welsh, Ryan Williams, D. Kirkpatrick, G. Powis (2008)
Molecular mechanisms for the activity of PX-478, an antitumor inhibitor of the hypoxia-inducible factor-1αMolecular Cancer Therapeutics, 7
- Publisher
- Springer Journals
- Copyright
- Copyright © 2011 by The Pharmaceutical Society of Korea and Springer Netherlands
- Subject
- Pharmacy; Pharmacology/Toxicology; Pharmacy
- ISSN
- 0253-6269
- eISSN
- 1976-3786
- DOI
- 10.1007/s12272-011-1021-3
- pmid
- 22076756
- Publisher site
- See Article on Publisher Site
Abstract
Hypoxia-inducible factor-1α (HIF-1α) is a transcription factor produced by tumor cells under hypoxic conditions, and a key regulator of a number of genes important in cancer biology. Over-expression of HIF-1α in human tumors is associated with poor prognosis and poor therapeutic outcomes and HIF-1α has been suggested as a novel target for cancer therapy. This article provides a review of PX-478 as the first novel HIF-1α inhibitor in clinical stage for the treatment of solid tumors.
Journal
Archives of Pharmacal Research – Springer Journals
Published: Oct 1, 2011